Subtype
Cutaneous Melanoma of the Extremity
CI-CAN-00002483Explore in graph →
15 active trials5 evidence items
- NCIt
- C155305
Loading cancer entity…
Subtype
CI-CAN-00002483Explore in graph →
Clinical trials
31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04462406 | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | active not recruiting | Phase 2 | 150 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | recruiting | Phase 2 | 112 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00937937 | Dinaciclib in Treating Patients With Stage IV Melanoma | active not recruiting | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03698019 | A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | active not recruiting | Phase 2 | 313 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07347444 | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | recruiting | Phase 2 | 99 | Emory UniversityOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06965231 | Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial(FUMS-EDJS2024) | recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT05512481 | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma | recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04331093 | Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma | recruiting | Phase 2 | 40 | Di WuOTHER | 1 | May 26, 2021 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials